# Jeffrey W. Clark

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-w-clark/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,558 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 90 |
| i10-index | 272 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5088474933 |
| ORCID iD | https://orcid.org/0000-0001-9524-3600 |
| Works | 910 |

## Researcher papers

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers](https://scholariq.org/papers/i-ros1-i-rearrangements-define-a-unique-molecular-class-of-lung-cancers/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors](https://scholariq.org/papers/phase-ii-study-of-temozolomide-and-thalidomide-in-patients-with-metastatic/)
- [<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib](https://scholariq.org/papers/i-met-i-amplification-identifies-a-small-and-aggressive-subgroup-of/)
- [Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer](https://scholariq.org/papers/minimal-residual-disease-detection-using-a-plasma-only-circulating-tumor-dna/)
- [Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases](https://scholariq.org/papers/anti-vegf-therapy-induces-ecm-remodeling-and-mechanical-barriers-to-therapy-in/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.